This program is focused on central activities required for the development of small organic molecules as cancer chemotherapeutic agents. Members of this program use a wide variety of approaches, including chemical, biochemical, cellular, and animal methods to design and discover drugs. These approaches include (but are not limited to):
Natural Product-Based Drug Design and Discovery – Synthesis of anticancer natural products and analogs thereof and biological studies on their mechanism of action.
Biologically-Targeted Drug Design – Design, synthesis, and biological evaluation of synthetic compounds as potential inhibitors of anticancer enzyme targets, and antagonists of anticancer receptors.
Screening of Biological Targets for Drug Discovery – Development and utilization of methods, including systems biology methods, for the high-throughput evaluation of potential anticancer agents.
- Preclinical Models for Drug Development – Evaluation of potential chemotherapeutic and chemopreventive agents in cellular and animal cancer models.
Specific examples of activities in this program include:
Development of new synthetic routes to natural products known to function as antitumor or chemopreventive agents.
Mechanistic evaluation of new anticancer natural products.
Design and synthesis of targeted protein kinase inhibitors.
Design and synthesis of inhibitors of post-translational modifications.
Design and synthesis of topoisomerase inhibitors.
Development of systems methods for discovery of novel potential anticancer targets.
- Studies of potential chemotherapeutic agents in mouse xenograph and other animal models.
Richard F. Borch, MCMP
David Colby, MCMP
Mark S. Cushman, MCMP
Mingji Dai, CHEM
V. Jo Davisson, MCMP
Jennifer Freeman, HSci
Philip L. Fuchs, CHEM
Arun K. Ghosh, CHEM; MCMP
Richard A. Gibbs, MCMP, Leader
Tony Hazbun, MCMP
Qing Jiang, F&N
Deborah W. Knapp, VCS, Co-leader
Markus Lill, MCMP
Mark A. Lipton, CHEM
Philip Low, CHEM
Sulma I. Mohammed, VPTH
Laurie Parker, MCMP
David J. Waters, VCS